Regeneron's FDA Approved Gene Therapy for Hearing Loss Amid Mixed Financial Results
Regeneron Pharmaceuticals (REGN) reported a 19% increase in first-quarter revenue, but its stock has fallen over 11% this year due to declining sales of its top-selling drug Eylea. The FDA recently approved Otarmeni, a gene therapy for hearing loss, which could provide future growth opportunities.
Topics: Biotech Drug Sales Earnings FDA Approval Regeneron Pharmaceuticals Revenue Growth Stock Performance